Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.400
-0.020 (-1.41%)
At close: Dec 5, 2025, 4:00 PM EST
1.380
-0.020 (-1.43%)
After-hours: Dec 5, 2025, 7:30 PM EST
Lexicon Pharmaceuticals Employees
Lexicon Pharmaceuticals had 103 employees as of December 31, 2024. The number of employees decreased by 182 or -63.86% compared to the previous year.
Employees
103
Change (1Y)
-182
Growth (1Y)
-63.86%
Revenue / Employee
$688,000
Profits / Employee
-$665,796
Market Cap
508.76M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LXRX News
- 18 hours ago - Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum - GlobeNewsWire
- 2 days ago - Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well - Seeking Alpha
- 10 days ago - Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences - GlobeNewsWire
- 16 days ago - Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 20 days ago - Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win - Seeking Alpha
- 24 days ago - Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference - GlobeNewsWire
- 27 days ago - Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 - GlobeNewsWire
- 4 weeks ago - Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2025 Earnings Call Transcript - Seeking Alpha